Fax: (713) 792-0608
Frontline treatment of localized osteosarcoma without methotrexate†
Results of the St. Jude Children's Research Hospital OS99 Trial
Article first published online: 10 JAN 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 12, pages 2770–2778, 15 June 2011
How to Cite
Daw, N. C., Neel, M. D., Rao, B. N., Billups, C. A., Wu, J., Jenkins, J. J., Quintana, J., Luchtman-Jones, L., Villarroel, M. and Santana, V. M. (2011), Frontline treatment of localized osteosarcoma without methotrexate. Cancer, 117: 2770–2778. doi: 10.1002/cncr.25715
We are indebted to Berlex Laboratories (Seattle, Wash) for providing granulocyte-macrophage–colony-stimulating factor (GM-CSF) for Chilean patients and to Wright Medical Company (Arlington, Tenn) for providing prostheses at a reduced price for Chilean patients. We acknowledge the valuable contributions of Charles B. Pratt, MD (deceased); Fredric A. Hoffer, MD; Carlos Rodriguez-Galindo, MD; Gaston K. Rivera, MD; Karen Wodowski, PNP; Vickie Given, RN; Dana Hawkins, RN, BSN, CCRC; Valerie McPherson, CCRP; and Debbie Poe, CCRP (St. Jude) and of Myriam Campbell, MD; Juan Jose Latorre, MD; Jesus Ortega, MD; and Emma Concha, MD (Chile). We thank Sharon Naron for editorial assistance. We thank Christine Wogan for her substantive editing of the manuscript.
- Issue published online: 7 JUN 2011
- Article first published online: 10 JAN 2011
- Manuscript Accepted: 7 SEP 2010
- Manuscript Revised: 15 JUL 2010
- Manuscript Received: 19 APR 2010
- renal failure;
The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue. In the previous OS91 trial, the treatment of localized disease with carboplatin, ifosfamide, doxorubicin, and HDMTX yielded outcomes comparable to those of cisplatin-based regimens and caused less toxicity. To build on this experience, the authors conducted a multi-institutional trial (OS99) that evaluated the efficacy of carboplatin, ifosfamide, and doxorubicin without HDMTX in patients with newly diagnosed, localized, resectable osteosarcoma.
Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m2 daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m2 daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m2 daily ×2 days) combined with ifosfamide or carboplatin.
A total of 72 eligible patients (median age, 13.4 years) were enrolled between May 1999 and May 2006. Forty of the 66 (60.6%) evaluable patients had good histologic responses (>90% tumor necrosis) to preoperative chemotherapy. The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98). The estimated 5-year survival rate was 78.9% ± 6.3% for the OS99 trial and 74.5% ± 6.3% for the OS91 trial (P = .40).
The regimen used in the OS99 trial was found to produce outcomes comparable to those of cisplatin-containing or HDMTX-containing regimens. This therapy offers a good alternative for patients, particularly those who demonstrate an intolerance of HDMTX, and for institutions that cannot provide pharmacokinetic monitoring for MTX. Cancer 2011. © 2011 American Cancer Society.